HOME >> BIOLOGY >> NEWS
Merck / AAAS announce 2005 winners for outstanding undergraduate research programs

WASHINGTON, DC- The Merck Company Foundation and the American Association for the Advancement of Science (AAAS) today announced winners of the 2005 awards for the Merck/AAAS Undergraduate Science Research Program.

This year's winners are Bowdoin College, Fairleigh Dickinson University, Furman University, Harvey Mudd College, Hope College, McNeese State University, North Central College, Northern Kentucky University, Oakland University, Otterbein College, Seattle University, St. Olaf College, University of the Sciences in Philadelphia, Ursinus College, and Vassar College.

The Merck/AAAS Undergraduate Science Research Program (USRP) is a national competitive awards program available in all 50 states, the District of Columbia, and Puerto Rico. Fifteen awards are made annually, and each award provides up to $60,000, paid over three years at $20,000 per year, for joint use by the biology and chemistry departments at each recipient institution. The funding supports research stipends for undergraduate students and ancillary programs that foster interactions between these departments.

Launched in 2000 as a national competition, awards will be made through 2009. This ten-year, $9 million initiative is funded by The Merck Company Foundation and administered by AAAS. The program goals are to:

  • enhance undergraduate education through research experiences that emphasize the interrelationship between chemistry and biology;
  • encourage students to pursue graduate education in chemistry and life sciences; and
  • foster undergraduate programs and activities that bridge chemistry and biology.

The program is open to qualified institutions in the United States and Puerto Rico that offer an American Chemical Society-certified program in chemistry and confer 10 or fewer graduate degrees annually in biology and chemistry combined. For additional information, send questions to merck@aaas.org
'"/>


17-Feb-2005


Page: 1 2

Related biology news :

1. Merck and AAAS announce 2007 winners of Outstanding Undergraduate Research Programs
2. Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration
3. Merck and AAAS announce 2006 winners for Outstanding Undergraduate Research Programs
4. Researchers gain support from Merck Sharp & Dohme for novel area of diabetes research
5. Nobel Laureate Sydney Brenner receives 2005 UCSD/Merck Life Science Achievement Award
6. Merck CEO Raymond Gilmartin to lecture at NJIT
7. Protein tyrosine phosphatases to be topic of ASBMB-Merck Award lecture
8. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
9. ESA announces 2007 award recipients
10. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
11. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced

Post Your Comments:
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: